NAR's executive committee approved it 2026-2028 strategic plan in a unanimous vote on Sunday during NAR NXT in Houston.

Recorded third quarter 2025 worldwide revenue of $384.0 million, GAAP fully diluted earnings per share of $0.41, adjusted fully diluted earnings ...

VCG. On Tuesday, Chinese Vice Premier He Lifeng met with Joseph Bae, co-CEO of US-based KKR Investment Group, according to ...

The fourth plenary session of the 20th Central Committee of the Communist Party of China (CPC) adopted the Recommendations of the Central Committee of the Communist Party of China for Formulating the ...

PrisMN Phase 2 trial of budoprutug in Primary Membranous Nephropathy (pMN) initiated Phase 1 trial of budoprutug subcutaneous formulation ...

Drugs approved by the FDA’s expanding program to expedite reviews for products in line with the Trump administration’s agenda ...

Kazia Therapeutics Limited (Nasdaq: KZIA), an oncology-focused drug development company, today announced that a patient ...

Journalists ask questions on Friday at a press conference in Beijing held by the Central Committee of the Communist Party of China on the guiding principles from the just-concluded fourth plenary ...

Kazia Therapeutics Limited (Nasdaq: KZIA), an oncology-focused drug development company, today announced that a patient with ...

Reports Significant Revenue Growth to $590K and Substantial Increase in Gross Profit to $575K Launched Sales of Arbli, the First FDA-Approved Ready-To-Use Liquid Formulation of Losartan for Hypertensi ...